Brain protein TSPO may hold key to blood sugar control
NCT ID NCT07682233
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study investigates whether a single dose of XBD173, a drug that binds to the TSPO protein, changes how the body processes glucose. Healthy volunteers aged 18 to 75 receive either XBD173 or a placebo on separate visits, then have their blood sugar and insulin levels measured after fasting and after drinking a glucose solution. The goal is to understand if activating TSPO influences glucose metabolism, which could inform future treatments for metabolic conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XBD173 (Emapunil)
What this could lead to
If TSPO activation changes glucose metabolism, this could point toward new treatments for metabolic disorders like diabetes.
What could go wrong
This is an early-phase study in healthy volunteers, so results may not apply to people with disease. The effect may be small or absent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEATHLY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NIHR Trust Imperial Clinical Research Facility
RECRUITINGLondon, W120NN, United Kingdom
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••